Challenges in development of nanoparticle-based therapeutics.

Strategic Platforms, Abraxis BioScience, 11755 Wilshire Blvd., Suite 2300, Los Angeles, California 90025, USA.
The AAPS Journal (Impact Factor: 4.39). 03/2012; 14(2):282-95. DOI: 10.1208/s12248-012-9339-4
Source: PubMed

ABSTRACT In recent years, nanotechnology has been increasingly applied to the area of drug development. Nanoparticle-based therapeutics can confer the ability to overcome biological barriers, effectively deliver hydrophobic drugs and biologics, and preferentially target sites of disease. However, despite these potential advantages, only a relatively small number of nanoparticle-based medicines have been approved for clinical use, with numerous challenges and hurdles at different stages of development. The complexity of nanoparticles as multi-component three dimensional constructs requires careful design and engineering, detailed orthogonal analysis methods, and reproducible scale-up and manufacturing process to achieve a consistent product with the intended physicochemical characteristics, biological behaviors, and pharmacological profiles. The safety and efficacy of nanomedicines can be influenced by minor variations in multiple parameters and need to be carefully examined in preclinical and clinical studies, particularly in context of the biodistribution, targeting to intended sites, and potential immune toxicities. Overall, nanomedicines may present additional development and regulatory considerations compared with conventional medicines, and while there is generally a lack of regulatory standards in the examination of nanoparticle-based medicines as a unique category of therapeutic agents, efforts are being made in this direction. This review summarizes challenges likely to be encountered during the development and approval of nanoparticle-based therapeutics, and discusses potential strategies for drug developers and regulatory agencies to accelerate the growth of this important field.

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: An as-synthesised hollow carbon nanoparticle (HC-NP) sample has been proved to be a relatively complex mixture, and its complexity can be reduced significantly by high-performance liquid chromatography. An unprecedented reduction in such complexity can reveal fractions of HC-NP with unique luminescence properties. While the UV-vis absorption profile for the HC-NP mixture is featureless, the HC-NP fractions do possess unique absorption bands and specific emission wavelengths. The HC-NP fractions are fully anatomised by matrix-assisted laser desorption/ionisation time-of-flight mass spectrometry, displaying their fragmentation mass ion features. The shell thickness and crystal lattices of the selected HC-NP fractions are determined as 6.13, 8.31, 2.22, and 8.66 nm, and 0.37, 0.35, 0.33, and 0.32 nm by transmission electron microscopy, respectively. The fractionated HC-NP show profound differences in emission quantum yield, allowing for brighter HC-NP to be isolated from an apparent low quantum yield mixture. Finally, red, green and blue emissive HC-NP are isolated from the as-synthesised HC-NP sample. They show good photostability and have been demonstrated to be excellent probes for cellular imaging.
    Nanoscale 06/2014; · 6.73 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Nanoemulsion dosage form serves as a vehicle for the delivery of active pharmaceutical ingredients and has attracted great attention in drug delivery and pharmacotherapy. In particular, nanoemulsions act as an excellent vehicle for poorly aqueous soluble drugs, which are otherwise difficult to formulate in conventional dosage forms. Nanoemulsions are submicron emulsions composed of generally regarded as safe grade excipients. Particle size at the nanoscale and larger surface area lead to some very interesting physical properties that can be exploited to overcome anatomical and physiological barriers associated in drug delivery to the complex diseases such as cancer. Along these lines, nanoemulsions have been engineered with specific attributes such as size, surface charge, prolonged blood circulation, target specific binding ability, and imaging capability. These attributes can be tuned to assist in delivering drug/imaging agents to the specific site of interest, based on active and passive targeting mechanisms. This review focuses on the current state of nanoemulsions in the translational research and its role in targeted cancer therapy. In addition, the production, physico-chemical characterization, and regulatory aspects of nanoemulsion are addressed.
    AAPS PharmSciTech 02/2014; · 1.58 Impact Factor
  • Molecular therapy : the journal of the American Society of Gene Therapy. 07/2014; 22(7):1239-40.


Available from